Education
About Us
Working with TipRanks
Follow Us
Absci Corp. (ABSI)
:ABSI
ABSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.01 - $6.33
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.35M
Market Cap
$408.20M
Enterprise Value$201.66M
Total Cash (Recent Filing)$117.46M
Total Debt (Recent Filing)$7.25M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Nov 05, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding149,522,640
10 Day Avg. Volume4,599,725
30 Day Avg. Volume4,347,258
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue48.73
Enterprise Value/Gross Profit-66.25
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$7.22Price Target Upside164.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PositionAbsci had $117.5mn in cash & equivalents at the end of 2Q25, with an estimated proforma cash balance of $182mn.
Potential PartnershipsManagement anticipates at least one partnership from a large pharma company, which could provide a source of non-dilutive capital.
Product DevelopmentFavorable ABS-201 readout could open the door to a multi-billion dollar opportunity in androgenetic alopecia.
Bears Say
Financial PerformanceAbsci reported lower-than-expected revenues and a larger net loss per share for 2Q25 compared to consensus estimates.
Market CompetitionABS-101 is on track for initial data, which should provide a key first look at the TL1A asset's positioning within the increasingly competitive TL1A landscape.
Stock RecommendationAnalyst's recommendation maintains a Buy Rating and is lowering the Price Target to $8 after accounting for dilution.
AbSci News
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.01 and its highest was $6.33 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $408.20M.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Nov 05, 2025 which is in 37 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on Aug 12, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.209 by -$0.031.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.2.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 149,522,640 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.209. Following the earnings report the stock price went up 5.051%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.22 (164.47% Upside)
$7.22 (164.47% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $433.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.57%
12-Months-Change
Fundamentals
Return on Equity
-57.39%
Trailing 12-Months
Asset Growth
-17.86%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and strategic partnerships, strengthening Absci's financial position and enhancing its drug development capabilities. However, the increase in R&D expenses and low revenue figures present challenges that need to be addressed.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$7.22
▲(164.47% Upside)
Technical Analysis
Omeros
―
Zevra Therapeutics
―
Stoke Therapeutics
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
7.73% Insiders
19.70% Mutual Funds
21.33% Other Institutional Investors
35.64% Public Companies and
Individual Investors